本公司已获准于联交所上市及买卖换股股份。债券预计将于2026年2月4日或前后获准于维也纳证券交易 所营运的Vienna MTF上市及买卖。 翰森制药(03692)发布公告，有关建议发行46.8亿港元于2033年到期的零息可换股债券。认购协议所载发 行债券的所有先决条件均已达成，且发行债券已于2026年2月3日成功落实。 ...

本公告及其所載資料不會直接或間接於或向美國（包括美國的領土及屬地、任何州及哥倫比亞 特區）發佈。本公告及其所載資料並不構成在美國境內購買、認購或出售證券的任何要約或招 攬或其組成部分。本公告中所述的證券並無亦不會根據一九三三年美國證券法（經修訂）（「美國 證券法」）或美國的任何州或其他司法管轄區的證券法律登記。本公告中所述的證券將根據美國 證券法S規例（「S規例」）在美國境外發售和出售，除非已進行登記或獲豁免遵守美國證券法的 登記規定，否則該等證券不得在美國境內發售或出售。本公告中所述的證券將不會於美國境內 或該等發售受到限制或禁止的任何其他司法管轄區境內公開發售。本公告或其所載資料並非金 錢、證券或其他對價的招攬，而倘為回應本公告或其所載資料而寄出金錢、證券或其他對價， 將不會獲接納。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成提呈收購、購買或認購本公司證券之邀請或招攬，或訂立協議以作 出上述行動之邀請，亦不應被視為提呈 ...

致：香港交易及結算所有限公司 公司名稱: 翰森製藥集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定/ ...

Core Viewpoint - Hansoh Pharmaceutical has been recognized for its outstanding performance in innovation, green production, environmental protection, social responsibility, and corporate governance, earning the title of "Green Leading Enterprise" and being included in the "Top 20 ESG Leading Samples" in Pudong New District's 2025 Environmental Performance Evaluation [1][4]. Group 1: Awards and Recognition - Hansoh Pharmaceutical is the only Chinese pharmaceutical company recognized as a "Green Leading Enterprise" among the evaluated entities [1][4]. - The "2025 ESG Leading Samples" evaluation was guided by various organizations, including the Shanghai Modern Service Industry Association and the Pudong New District Business Committee, with support from the Ministry of Commerce [2][5]. - The company has received high recognition from global authoritative institutions, maintaining an MSCI AA rating for several years and being listed in the S&P Global "Sustainability Yearbook" as one of the top 1% in the industry [3][6]. Group 2: ESG Practices and Contributions - Hansoh Pharmaceutical has significantly improved diagnostic capabilities and created social welfare in the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD), which contributed to its selection in the "Top 20 ESG Leading Samples" [2][5]. - The Pudong New District has been enhancing its ESG evaluation system, encouraging enterprises to align with international standards and systematically improve their environmental, social, and governance development levels [2][5]. - As a key enterprise in the region, Hansoh Pharmaceutical actively participates in and shares its ESG practices, providing valuable examples and development paths for the pharmaceutical and related industries [2][5]. Group 3: Environmental Information Disclosure - In the 2025 Environmental Information Disclosure Ratings released by the global authoritative platform CDP, Hansoh Pharmaceutical achieved a dual B rating in climate change and water security, maintaining a leading position among Chinese pharmaceutical companies [3][7].

Group 1 - The event themed "ESG-driven New Productive Forces, Building a New Ecosystem for the Pudong Headquarters Economy" was held in Shanghai, focusing on sustainable development and ESG-related themes [1] - The "2025 Pudong New Area Sustainable Development (ESG) Leading Sample" and the "Pudong New Area ESG Industry Ecological Innovation Competition" were announced, with Hansoh Pharmaceutical recognized for its practices in improving diagnosis and treatment levels for Neuromyelitis Optica Spectrum Disorders (NMOSD) [1] Group 2 - NMOSD is a rare autoimmune disease affecting the central nervous system, with an incidence rate of approximately (0.5-3.4)/100,000 globally, and its treatment is complex [2] - Hansoh Pharmaceutical introduced the world's first humanized CD19 monoclonal antibody, XinYue® (Inalizumab Injection), for treating adult NMOSD patients, which was approved in China in 2022 [2] - The company has also received approval for a second rare disease indication for XinYue® in treating adult patients with Immunoglobulin G4-related disease (IgG4-RD) and has a third application for generalized Myasthenia Gravis (gMG) under review [2] Group 3 - As a leading innovative pharmaceutical company in China, Hansoh Pharmaceutical is committed to enhancing the accessibility and affordability of rare disease medications [3] - The company has increased its investment in R&D for "anti-tumor, anti-infection, central nervous system, metabolic, and autoimmune" diseases, with 7 innovative drugs included in the national medical insurance directory [3] - By the first half of 2025, sales revenue from innovative drugs and cooperative products accounted for over 82.7% of the company's total revenue, highlighting innovation as a core driver of its mission and vision [3] - Hansoh Pharmaceutical has received high recognition for its performance in corporate governance, R&D innovation, environmental protection, social responsibility, and talent development, achieving MSCI AA rating and inclusion in the S&P Global Sustainability Yearbook [3]

Core Viewpoint - Hansoh Pharmaceutical (03692) has experienced a decline of over 5%, currently trading at HKD 38.48, with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - Approximately 65% of the proceeds will be allocated for drug research and development and licensing [1] - About 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen its stock price decline over 5%, currently trading at HKD 38.48 with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue zero-coupon convertible bonds worth HKD 4.68 billion, maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - About 65% of the proceeds will be allocated for drug research and development and licensing [1] - Approximately 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

翰森制药(03692)发布公告，于2026年1月26日(交易时段后)，公司与经办人订立认购协议。根据认购协 议，(其中包括)公司已有条件同意向经办人(或根据经办人指示)发行，而经办人亦已有条件与公司商定 个别而非共同认购和支付债券，惟须遵守认购协议所载的若干条件。 公司将向维也纳证券交易所营运的Vienna MTF申请批准债券上市及买卖。公司亦将向联交所申请批准 换股股份在联交所上市及买卖。 债券可依照条款和条件转换成换股股份。假设债券按每股股份的初始换股价57.39港元悉数转换，且公 司概无进一步发行股份，债券将可转换成8154.73万股股份(总面值约815港元)，占公司于本公告日期已 发行股本约1.35%，并占经债券悉数转换时发行换股股份扩大后的公司于本公告日期已发行股本约 1.33%。于转换债券时予以发行的换股股份将在所有方面与相关登记日当时已发行股份享同等地位，并 享有相同的权利和特权。 经扣除佣金及其他相关费用后，预计债券所得款项净额约46.4亿港元，按照初始换股价计算，每股换股 股份的发行价格净额约56.90港元。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has announced a subscription agreement with an underwriter, allowing the company to issue convertible bonds, which can be converted into shares at a specified price, potentially raising significant capital [1] Group 1: Subscription Agreement Details - The company has conditionally agreed to issue bonds to the underwriter, who will subscribe individually rather than collectively, subject to the terms of the agreement [1] - The bonds can be converted into shares at an initial conversion price of HKD 57.39 per share, potentially resulting in the issuance of approximately 81.55 million shares, representing about 1.35% of the company's existing share capital as of the announcement date [1] - The net proceeds from the bond issuance are expected to be approximately HKD 4.64 billion, with a net issue price of about HKD 56.90 per share based on the initial conversion price [1] Group 2: Listing and Trading - The company plans to apply for the listing and trading of the bonds on the Vienna MTF operated by the Vienna Stock Exchange [1] - Additionally, the company will seek approval for the listing and trading of the converted shares on the Hong Kong Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成提呈收購、購買或認購本公司證券之邀請或招攬，或訂立協議以作 出上述行動之邀請，亦不應被視為提呈收購、購買或認購本公司任何證券之邀請。 本公告及其所載資料不會直接或間接於或向美國（包括美國的領土及屬地、任何州及哥倫比亞 特區）發佈。本公告及其所載資料並不構成在美國境內購買、認購或出售證券的任何要約或招 攬或其組成部分。本公告中所述的證券並無亦不會根據1933年美國證券法（經不時修訂）（「美國 證券法」）或美國的任何州或其他司法管轄區的證券法律登記。本公告中所述的證券將根據美國 證券法S規例（「S規例」）在美國境外發售和出售，除非已進行登記或獲豁免遵守美國證券法的 登記規定，否則該等證券不得在美國境內發售或出售。本公告中所述的證券將不會於美國境內 或該等發售受到限制或禁止的任何其他司法管轄區境內公開發售。本公告或其所載資料並非金 錢、證券或其他對價的招攬，而倘為回應本公告或其所載資料而 ...